| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
|
J Clin Oncol
|
2006
|
1.69
|
|
2
|
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms.
|
Oncotarget
|
2014
|
1.34
|
|
3
|
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience.
|
Clin Cancer Res
|
2012
|
1.29
|
|
4
|
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.
|
Clin Cancer Res
|
2012
|
1.27
|
|
5
|
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
|
Clin Cancer Res
|
2011
|
1.26
|
|
6
|
Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy.
|
Mol Cell Biol
|
2009
|
1.15
|
|
7
|
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
|
Clin Cancer Res
|
2009
|
1.04
|
|
8
|
Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.
|
Clin Cancer Res
|
2010
|
1.01
|
|
9
|
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
|
Clin Cancer Res
|
2009
|
1.00
|
|
10
|
Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.
|
Mol Cancer Ther
|
2011
|
0.98
|
|
11
|
A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
|
Oncologist
|
2014
|
0.93
|
|
12
|
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
|
Clin Cancer Res
|
2007
|
0.91
|
|
13
|
Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.
|
Cancer Chemother Pharmacol
|
2010
|
0.90
|
|
14
|
Ethnic disparities in adherence to breast cancer survivorship surveillance care.
|
Cancer
|
2013
|
0.86
|
|
15
|
Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience.
|
Clin Breast Cancer
|
2010
|
0.83
|
|
16
|
Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors.
|
Clin Cancer Res
|
2013
|
0.82
|
|
17
|
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
|
Invest New Drugs
|
2013
|
0.80
|
|
18
|
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.
|
Invest New Drugs
|
2015
|
0.79
|
|
19
|
Improving the institutional submission and approval process for clinical research protocols in oncology.
|
J Clin Oncol
|
2007
|
0.78
|
|
20
|
Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial.
|
Mol Cancer Ther
|
2011
|
0.78
|
|
21
|
Metaplastic breast cancer: clinical overview and molecular aberrations for potential targeted therapy.
|
Curr Oncol Rep
|
2015
|
0.76
|
|
22
|
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.
|
Invest New Drugs
|
2014
|
0.75
|
|
23
|
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.
|
Clin Cancer Res
|
2013
|
0.75
|
|
24
|
Posterior reversible encephalopathy syndrome: more than meets the eye.
|
J Clin Oncol
|
2013
|
0.75
|